The predictive value of MP hypertension monitoring system combined with PLGF and PI for preeclampsia

doi:10.11958/20231021

Abstract

Abstract:

Objective To establish a clinical prediction model for preeclampsia by monitoring risk rating of MP gestation and levels of placental growth factor (PLGF) combined with uterine artery pulsatility index (PI) measured during examination of fetal nuchal translucency (NT). Methods Twenty-four patients with preeclampsia who met the inclusion criteria were selected as the case group, and 95 healthy pregnant women during the same period were randomly selected as the control group. Serum concentrations of PLGF, uterine artery PI values measured by quantitative immunofluorescence assay at 11-14 weeks of gestation, risk ratings for MP hypertension monitoring at 11-20 weeks of gestation, and other relevant data, BMI, age, gestation, mode of delivery, neonatal birth weight and Apgar score were collected in the two groups. Results Results of univariate regression analysis showed that BMI, age, high risk of PI, MP and PLGF<12 were influencing factors for adverse outcomes. Results of multivariate regression analysis showed that high PI, medium high risk in MP and PLGF<12 were independent risk factors for adverse outcomes. The prediction model of PE established was logit (P) = -15.767 + 0.020 × PI + 0.072 × MP risk (medium-high risk = 1, low risk = 0) + 0.181 × PLGF classification (<12 = 1, ≥12 = 0), with an AUC area of 0.883, specificity of 0.816 and sensitivity of 0.846. Conclusion The combination of PI, MP risk and PLGF to establish a clinical predictive model for preeclampsia has certain value, and its combined predictive value is higher than that of single application.

Key words: pre-eclampsia, models, statistical, hypertension, pregnancy-induced, placenta growth factor, MP hypertension monitoring system, pulsatility index

CLC Number:

R714.252

Figures/Tables 7

References 27

[1]	POON L C, SHENNAN A, HYETT J A, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia:A pragmatic guide for first-trimester screening and prevention[J]. Int J Gynaecol Obstet, 2019, 145(Suppl 1):1-33. doi:10.1002/ijgo.12802.
[2]	KASSAN M, WECKER A, KADOWITZ P, et al. CD4⁺CD25⁺Foxp3 regulatory T cells and vascular dysfunction in hypertension[J]. J Hypertens, 2013, 31(10):1939-1943. doi:10.1097/HJH.0b013e328362feb7.
[3]	NEVERS T, KALKUNTE S, SHARMA S. Uterine regulatory T cells,IL-10 and hypertension[J]. Am J Reprod Immunol, 2011, 66(Suppl 1):88-92. doi:10.1111/j.1600-0897.2011.01040.x.
[4]	Matsubara K, Matsubara Y, Uchikura Y, et al. HMGAl is a potential driver of preeclampsia pathogenesis by interference with extravillous trophoblasts invasion[J]. Biomolecules, 2021, 11(6):822. doi:10.3390/biom11060822.
[5]	岳巾晶, 曾莹, 郭晓珮, 等. miR-155通过调控PKG1影响滋养细胞生物学功能并参与子痫前期的机制探讨[J]. 天津医药, 2023, 51(9):928-934.
	YUE J J, ZENG Y, GUO X P, et al. MiR-155 affects the biological functions of trophoblastic cells through regulating cGMP-dependent kinase 1 and is involved in the mechanism of preeclampsia[J]. Tianjin Med J, 2023, 51(9):928-934. doi:10.11958/20221869.
[6]	韩贞艳, 关红琼. 子痫前期患者的胎盘环状RNA表达谱及与病情的相关性[J]. 天津医药, 2023, 51(5):513-517.
	HAN Z Y, GUAN H Q. The expression profile of circular RNA in placenta of patients with preeclampsia and its correlation with the patient’s condition[J]. Tianjin Med J, 2023, 51(5):513-517. doi:10.11958/20221313.
[7]	鲁超, 汪俊丽. 血清白蛋白、前白蛋白、血红蛋白及尿液β2-微球蛋白对不同类型子痫前期的预测价值[J]. 临床与病理杂志, 2022, 42(6):1355-1362.
	LU C, WANG J L. Predictive value of serum albumin,prealbumin,hemoglobin and urine β2-microglobulin in different types of preeclampsia[J]. International Journal of Pathology and Clinical Medicine, 2022, 42(6):1355-1362. doi:10.3978/j.issn.2095-6959.2022.06.014.
[8]	鲍瀛, 张凤美, 张蝶. 胎盘生长因子在临床疾病诊断中的研究进展[J]. 吉林医学, 2022, 43(4):1087-1089.
	BAO Y, ZHANG F M, ZHANG D. Research progress of placental growth factor in clinical[J]. Jilin Medical Journal, 2022, 43(4):1087-1089. doi:10.3969/j.issn.1004-0412.2022.04.089.
[9]	陈佳, 郭静, 韩悦, 等. 联合检测妊娠早中期孕妇血清PAPP-A、PLGF及子宫动脉血流参数预测子痫前期的临床意义[J]. 解放军医药杂志, 2021, 33(2):60-64.
	CHEN J, GUO J, HAN Y, et al. Clinical significance of combined detection of serum PAPP-A,PLGF and uterine artery blood flow parame-ters in pregnant women in early and mid-pregnancy in prediction of preeclampsia[J]. Medical & Pharmaceutical Journal of Chinese People's Liberation Army, 2021, 33(2):60-64. doi:10.3969/j.issn.2095-140X.2021.02.014.
[10]	MACDOMNALD T M, WALKER S P, HANNAN N J, et al. Clinical tools and biomarkers to predict preeclampsia[J]. EBio Medicine, 2022, 75:103780. doi:10.1016/j.ebiom.2021.103780.
[11]	沈新丽. 联合检测妊娠早中期孕妇血清β-hCG、PAPP-A、sFlt-1及PLGF对预测子痫前期的意义[J]. 中国妇幼保健, 2018, 33(15):3412-3415.
	SHEN X L. Joint detection of serum from pregnant women in the early and middle stages of pregnancy β- The significance of hCG,PAPP-A,sFlt-1,and PLGF in predicting preeclampsia[J]. Maternal & Child Health Care of China, 2018, 33(15):3412-3415. doi:10.7620/zgfybj.j.issn.1001-4411.2018.15.16.
[12]	CHAEMSAITHONG P, SAHOTA D S, POON L C. First trimester preeclampsia screening and prediction[J]. Am J Obstet Gynecol, 2022, 226(2S):S1071-S1097.e2. doi:10.1016/j.ajog.2020.07.020.
[13]	褚翠雯, 陈爱萍, 李坤. 超声子宫动脉血流指标评估子痫前期孕妇母胎循环及与妊娠结局的相关性[J]. 中国计划生育学杂志, 2022, 30(7):1569-1573.
	CHU C W, CHEN A P, LI K. Maternal and fetal circulation situation evaluated by the uterine artery blood flow indexes of ultrasonography and their cor-relation with the pregnancy outcomes[J]. Chinese Journal of Family Planning, 2022, 30(7):1569-1573. doi:10.3969/j.issn.1004-8189.2022.07.023.
[14]	蔡莉娜, 刘剑波, 吴树彪, 等. 可溶性血管内皮生长因子受体-1/胎盘生长因子与子宫动脉搏动指数联合预测子痫前期的临床价值研究[J]. 中国全科医学, 2018, 21(7):827-830.
	CAI L N, LIU J B, WU S B, et al. Predicative value of sFlt-1/PLGF ratio and uterine artery pi for preeclampsia[J]. Chinese General Practice, 2018, 21(7):827-830. doi:10.3969/j.issn.1007-9572.2018.07.015.
[15]	PEDROSO M A, PALMER K R, HODGES R J, et al. Uterine artery doppler in screening for preeclampsia and fetal growth restriction[J]. Rev Bras Ginecol Obstet, 2018, 40(5):287-293. doi:10.1055/s-0038-1660777.
[16]	王勇, 李传刚. 微小RNA-18a联合子宫动脉血流参数对早发型子痫前期的预测价值[J]. 天津医药, 2021, 49(12):1311-1315.
	WANG Y, LI C G. The predictive value of microRNA-18a combined with uterine artery blood flow parameters for early-onset preeclampsia[J]. Tianjin Med J, 2021, 49(12):1311-1315.
[17]	张秀丽, 何宏舸, 王伟伟, 等. MP妊高征监测系统在妊娠期高血压疾病预测及预防中的应用价值[J]. 临床医学, 2022, 42(4):15-17.
	ZHANG X L, HE H G, WANG W W, et al. Clinical application of MP pregnancy induced hypertension monitoring system in prediction and prevention of pregnancy induced hypertension[J]. Clinical Medicine, 2022, 42(4):15-17. doi:10.19528/j.issn.1003-3548.2022.04.005.
[18]	REDMAN C W G. The six stages of pre-eclampsia[J]. Pregnancy Hypertens, 2014, 4:246. doi:10.1016/j.preghy.2014.04.020.
[19]	AVORGBEDOR F, SILVA S, MCCOY T P, et al. Hypertension and infant outcomes: North Carolina pregnancy risks assessment monitoring system data[J]. Pregnancy Hypertens, 2022, 28:189-193. doi:10.1016/j.preghy.2022.05.004.
[20]	李晶, 范卓然, 张俊农, 等. 早产型子痫前期及慢性高血压并发子痫前期患者的临床特征及TyG指数对比研究[J]. 天津医药, 2023, 51(2):190-193.
	LI J, FAN Z R, ZHANG J N, et al. Comparative study on clinical characteristics and TyG index in patients with premature preeclampsia and chronic hypertension complicated with preeclampsia[J]. Tianjin Med J, 2023, 51(2):190-193. doi:10.11958/20220717.
[21]	任玉洁. 血清PLGF、SFLT-1、MAP及UAPI对预测子痫前期的临床应用价值[J]. 现代诊断与治疗, 2022, 33(3):320-323.
	REN Y J. Clinical Application value of serum PLGF,SFLT-1,MAP and UAPI in predicting preeclampsia[J]. Modern Diagnosis & Treatment, 2022, 33(3):320-323.
[22]	孙文静, 胡孟彩, 崔世红, 等. 妊娠相关血浆蛋白A、胎盘生长因子联合胆红素对子痫前期的预测价值[J]. 中外医学研究, 2021, 19(4):74-77.
	SUN W J, HU M C, CUI S H, et al. Predictive value of PAPP-A,PLGF and bilirubin in preeclampsia[J]. Chinese and Foreign Medical Research, 2021, 19(4):74-77. doi:10.14033/j.cnki.cfmr.2021.04.025.
[23]	杨冬梅. 胎盘生长因子在早期妊娠中的研究进展[J]. 天津医科大学学报, 2022, 28(3):339-342.
	YANG D M. Research progress on placental growth factor in early pregnancy[J]. Journal of Tianjin Medical University, 2022, 28(3):339-342.
[24]	刘景雁, 郭永华, 肖保军, 等. 孕早期子宫动脉测量预测孕中晚期妊娠期高血压价值[J]. 中国计划生育学杂志, 2022, 30(6):1357-1359,1364.
	LIU J Y, GUO Y H, XIAO B J, et al. Value of uterine artery measurement of pregnant women during the first trimester of pregnancy for predicting their gesta-tional hypertension occurrence during the second and third trimester of pregnancy[J]. Chinese Journal of Family Planning, 2022, 30(6):1357-1359,1364. doi:10.3969/j.issn.1004-8189.2022.06.031.
[25]	VELAUTHAR L, PLANA M N, KALIDINDI M, et al. First trimester uterine artery Doppler and adverse pregnancy outcome:a meta-analysis involving 55,974 women[J]. Ultrasound Obstet Gynecol, 2014, 43(5):500-507. doi:10.1002/uog.13275.
[26]	宋岚, 尤佳. 动态血压监测联合妊高征预测系统在妊娠期高血压疾病管理中的应用效果[J]. 临床医学研究与实践, 2019, 4(7):123-124.
	SONG L, YOU J. Application effect of ambulatory blood pressure monitoring combined with pregnancy induced hypertension prediction system in the management of pregnancy induced hypertension[J]. Clinical Research and Practice, 2019, 4(7):123-124. doi:10.19347/j.cnki.2096-1413.201907051.
[27]	朱爱玲, 张东红, 王俊霞. MP妊娠高血压综合征监测系统13200例临床观察[J]. 实用医学杂志, 2013, 29(20):3358-3360.
	ZHU A L, ZHANG D H, WANG J X. Clinical observation on 13200 cases of MP pregnancy induced hypertension syndrome monitoring system[J]. The Journal of Practical Medicine, 2013, 29(20):3358-3360. doi:10.3969/j.issn.1006-5725.2013.20.035.

组别	n		BMI/（kg/m²）				年龄/岁				孕次/次
对照组	95		24.65（22.46，27.12）				31.00（29.50，34.00）				2（1，3）
病例组	24		25.93（24.20，27.85）				34.00（31.00，37.00）				3（1，4）
Z			2.102^＊				3.184^＊＊				1.743
组别		外周阻力/PRU				血液黏度/CP				左RI
对照组		4.50（3.93，4.85）				1.07（0.76，1.59）				0.78（0.72，0.82）
病例组		4.57（4.22，4.78）				1.25（0.96，1.82）				0.78（0.74，0.84）
Z		1.712				0.825				0.735
组别				左S/D				右RI
对照组				4.60（3.60，5.70）				0.77（0.73，0.83）
病例组				4.60（3.80，6.35）				0.79（0.71，0.85）
Z				0.617				0.701
组别					右S/D				PI
对照组					4.30（3.70，5.90）				1.80±0.42
病例组					4.65（3.40，6.73）				2.18±0.51
Z或t					0.779				4.764^＊

组别	n		BMI/（kg/m²）				年龄/岁				孕次/次
对照组	95		24.65（22.46，27.12）				31.00（29.50，34.00）				2（1，3）
病例组	24		25.93（24.20，27.85）				34.00（31.00，37.00）				3（1，4）
Z			2.102^＊				3.184^＊＊				1.743
组别		外周阻力/PRU				血液黏度/CP				左RI
对照组		4.50（3.93，4.85）				1.07（0.76，1.59）				0.78（0.72，0.82）
病例组		4.57（4.22，4.78）				1.25（0.96，1.82）				0.78（0.74，0.84）
Z		1.712				0.825				0.735
组别				左S/D				右RI
对照组				4.60（3.60，5.70）				0.77（0.73，0.83）
病例组				4.60（3.80，6.35）				0.79（0.71，0.85）
Z				0.617				0.701
组别					右S/D				PI
对照组					4.30（3.70，5.90）				1.80±0.42
病例组					4.65（3.40，6.73）				2.18±0.51
Z或t					0.779				4.764^＊

组别	n	PLGF（ng/L）		MP风险
组别	n	<12	≥12	低风险	中高风险
对照组	95	11（11.6）	84（88.4）	72（75.8）	23（24.2）
病例组	24	15（52.5）	9（37.5）	13（54.2）	11（45.8）
χ²		9.207^＊＊		4.389^＊

组别	n	PLGF（ng/L）		MP风险
组别	n	<12	≥12	低风险	中高风险
对照组	95	11（11.6）	84（88.4）	72（75.8）	23（24.2）
病例组	24	15（52.5）	9（37.5）	13（54.2）	11（45.8）
χ²		9.207^＊＊		4.389^＊

组别		n	分娩方式			新生儿出生体质量/g
组别		n	顺产	剖宫产		新生儿出生体质量/g
对照组		95	40（42.1）	55（57.9）		3 192.78±468.38
病例组		24	1（4.2）	23（95.8）		2 194.76±848.12
χ²、Z或t'			12.211^＊＊			7.765^＊＊
组别	Apgar评分/分
组别	1 min				5 min		10 min
对照组	10.0（10.0，10.0）				10.0（10.0，10.0）		10.0（10.0，10.0）
病例组	10.0（8.0，10.0）				10.0（9.0，10.0）		10.0（10.0，10.0）
χ²、Z或t'	3.939^＊＊				3.553^＊＊		4.030^＊＊